Cardio Diagnostics Holdings Inc is trading at $2.48 (+5.5%) in pre-market as the stock extends a sharp multi-day rally driven by upcoming industry presentations.
- The primary catalyst is the company’s plan to pitch its AI-driven heart-disease blood tests at four national benefits conferences this month, which has fueled sustained investor interest.
- The stock has shown significant speculative strength over the past week, posting gains of 10.33% on June 2, 12.70% on June 1, and 9.94% on May 26.
- With no new overnight company-specific announcements, the current price action appears to be a continuation of the momentum surrounding the company's clinical roadmap.